Tinzaparin
Metastatic Malignant Neoplasm In The Colon
Explore 65 assets in Metastatic Malignant Neoplasm In The Colon →Floatz Rating
CCC54/100
Confidence
Indicative
Sponsor
Galician Research Group on Digestive Tumors
Modality
other_biological
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05625932CT.gov TINzaparin Prophylaxis in Patients With Metastatic Colorectal Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Metastatic Malignant Neoplasm In The Colon
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tinzaparin (this asset) | Galician Research Group on Digestive Tumors | P3 | CCC · 54 |
| Binimetinib | Pierre Fabre Medicament | P3 | BB |
| Irinotecan | Oncolytics Biotech | P4 | BB |
| Aflibercept | Sanofi | P3 | BB |
| Adriamycin | Northwell Health | P4 | B |
| Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer | Centre Georges Francois Leclerc | P2 | B |
| Durvalumab | University of Iowa | P2 | B |
| Famitinib | Jiangsu HengRui Medicine Co., Ltd. | P3 | B |
| Tivantinib | Armando Santoro, MD | P2 | B |
+42 more in the Metastatic Malignant Neoplasm In The Colon cohort
Other indications for Tinzaparin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Pancreatic Neoplasm | — | P4 | BBB · 72 |
| Thrombotic Disease | — | P4 | BB · 65 |
| Venous Thromboembolism | — | P3 | BB · 64 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- BinimetinibPierre Fabre MedicamentBB
- IrinotecanOncolytics BiotechBB
- AfliberceptSanofiBB
- AdriamycinNorthwell HealthB
- Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, DimerCentre Georges Francois LeclercB
Citation
Floatz Terminal. Tinzaparin in Metastatic Malignant Neoplasm In The Colon. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tinzaparin-metastatic-malignant-neoplasm-in-the-colon
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →